Published in:
Open Access
01-12-2015 | Poster presentation
Dendritic cell-derived exosomes (Dex) are potential biomarkers of response to Ipilimumab in metastatic melanoma
Authors:
Stefania Stucci, Marco Tucci, Paolo Antonio Ascierto, Anna Passarelli, Capone Mariaelena, Gabriele Madonna, Simeone Ester, Antonio Maria Grimaldi, Franco Silvestris
Published in:
Journal of Translational Medicine
|
Special Issue 1/2015
Login to get access
Excerpt
Chemotherapy and vaccination with tumor-loaded dendritic cells (DCs) show poor impact on overall survival (OS) in metastatic melanoma1,2. Ipilimumab (IPI) improves OS throughout the blockade of CTLA4-mediated inhibitory signals in T-cells and restores the efficiency of the antigenic cross-priming by mature (m) DCs3. However, variation of immune cells to evaluate the response to IPI does not reflect the T-cell activation and is a modest predictor of clinical response. Recent studies in human and experimental melanoma demonstrated that mDCs release endomysial microvescicles namely dexosomes (Dex) showing a functional anti-melanoma activity as well as an antigenic profile resembling that of circulating mDCs including CD40, CD80 and CD86 co-stimulatory molecules. …
